← Leaderboards
Heide L Ford
University Of Colorado Denver
$14,422,349
Attributed
$20,945,776
Total exposure
17
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,945,776 · 17
By mechanism
R01$18,457,393 · 8
R21$743,751 · 2
R41$692,595 · 2
P01$471,890 · 1
R35$421,200 · 1
R03$148,947 · 2
Top collaborators
- Rui Zhao16 shared
- Michael T Lewis6 shared
- Kristin Bruk Artinger5 shared
- Kian Behbakht4 shared
- Andrew M Thorburn4 shared
- Xiang Wang1 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Michael T Lewis$21,208,742
- Kian Behbakht$555,749
- Kathleen O'Neill$421,117
- Davalyn Renee Powell$78,041
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsNeoplasm MetastasisTumorMediatingCellsIn VivoGrowthOverexpressionMalignant Breast NeoplasmTranscription FactorEmbryonic DevelopmentMolecularMouse ModelMammary NeoplasmsTumor ProgressionTissuesSignal TransductionLeadMigrationPlayNeoplastic CellStem CellsCancer CellNew Therapeutic Target
Grant awards (68)
Reprogramming myogenic regulatory factors in RMS to promote differentiation and halt growth$836,041
R01 · FY2025 · CA · contact PI
Deciphering the role of EYA3/PP2A in triple negative breast cancer metastasis$647,118
R01 · FY2025 · CA · contact PI
Understanding Epigenetic Regulation of Copy Number Heterogeneity$421,200
R35 · FY2025 · GM · contact PI
Reprogramming myogenic regulatory factors in RMS to promote differentiation and halt growth$627,696
R01 · FY2024 · CA · contact PI
Preclinical Studies to Develop an Eya2 Tyr Phosphatase Inhibitor as a Novel Medulloblastoma Therapeutic$399,709
R41 · FY2024 · CA · contact PI
Reprogramming myogenic regulatory factors in RMS to promote differentiation and halt growth$672,698
R01 · FY2023 · CA · contact PI
Deciphering Mechanisms by which Tumor Cells Collaborate to Mediate Metastasis$601,506
R01 · FY2023 · CA · contact PI
Deciphering Mechanisms by which Tumor Cells Collaborate to Mediate Metastasis$601,506
R01 · FY2022 · CA · contact PI
Role of Eya3 in regulating the immune microenvironment to promote breast tumor progression$620,565
R01 · FY2021 · CA · contact PI
Deciphering Mechanisms by which Tumor Cells Collaborate to Mediate Metastasis$613,781
R01 · FY2021 · CA · contact PI
Examining the EYA2/MYC axis in Group 3 Medulloblastoma$425,149
R01 · FY2021 · NS · contact PI
Deciphering Mechanisms by which Tumor Cells Collaborate to Mediate Metastasis$694,114
R01 · FY2020 · CA · contact PI
Role of Eya3 in regulating the immune microenvironment to promote breast tumor progression$620,565
R01 · FY2020 · CA · contact PI
Examining the EYA2/MYC axis in Group 3 Medulloblastoma$425,149
R01 · FY2020 · NS · contact PI
Deciphering Mechanisms by which Tumor Cells Collaborate to Mediate Metastasis$627,656
R01 · FY2019 · CA · contact PI
Role of Eya3 in regulating the immune microenvironment to promote breast tumor progression$601,947
R01 · FY2019 · CA · contact PI
Examining the EYA2/MYC axis in Group 3 Medulloblastoma$425,149
R01 · FY2019 · NS · contact PI
Deciphering Mechanisms by which Tumor Cells Collaborate to Mediate Metastasis$29,978
R01 · FY2019 · CA · contact PI
Role of Eya3 in regulating the immune microenvironment to promote breast tumor progression$620,565
R01 · FY2018 · CA · contact PI
Examining the EYA2/MYC axis in Group 3 Medulloblastoma$360,514
R01 · FY2018 · NS · contact PI
Role of Eya3 in regulating the immune microenvironment to promote breast tumor progression$51,338
R01 · FY2018 · CA · contact PI
Role of Eya3 in regulating the immune microenvironment to promote breast tumor progression$24,146
R01 · FY2018 · CA · contact PI
Role of Eya3 in regulating the immune microenvironment to promote breast tumor progression$614,111
R01 · FY2017 · CA · contact PI
Role of Six1 and the miR106b 25 cluster in EMT and Tumor Progression$371,491
R01 · FY2017 · CA · contact PI
Using zebrafish to study the role of six1a/b and microRNA-30a in rhabdomyosarcoma (RMS) initiation and progression$202,928
R21 · FY2017 · CA · contact PI
2017 Mammary Gland Biology Gordon Research Conference & Gordon Research Seminar$10,000
R13 · FY2017 · CA · contact PI
Role of Six1 and the miR106b 25 cluster in EMT and Tumor Progression$371,956
R01 · FY2016 · CA · contact PI
Developing cancer therapies through targeting the Six1/Eya transcriptional complex$202,928
R21 · FY2016 · CA · contact PI
Using zebrafish to study the role of six1a/b and microRNA-30a in rhabdomyosarcoma (RMS) initiation and progression$169,106
R21 · FY2016 · CA · contact PI
Role of Six1 and the miR106b 25 cluster in EMT and Tumor Progression$371,956
R01 · FY2015 · CA · contact PI
The Six1/Eya Transcriptional complex as a mediator of lymphangiogenesis and lymph$312,416
R01 · FY2015 · CA · contact PI
Developing cancer therapies through targeting the Six1/Eya transcriptional complex$168,789
R21 · FY2015 · CA · contact PI
The Six1/Eya Transcriptional complex as a mediator of lymphangiogenesis and lymph$25,828
R01 · FY2015 · CA · contact PI
The Six1/Eya Transcriptional complex as a mediator of lymphangiogenesis and lymph$303,044
R01 · FY2014 · CA · contact PI
Role of Six1 and the miR106b 25 cluster in EMT and Tumor Progression$256,092
R01 · FY2014 · CA · contact PI
The Six1/Eya Transcriptional complex as a mediator of lymphangiogenesis and lymph$47,404
R01 · FY2014 · CA · contact PI
The Six1/Eya Transcriptional complex as a mediator of lymphangiogenesis and lymph$293,671
R01 · FY2013 · CA · contact PI
The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors$292,886
R41 · FY2013 · CA · contact PI
Role of Six1 and the miR106b 25 cluster in EMT and Tumor Progression$263,171
R01 · FY2013 · CA · contact PI
The Six1/Eya Transcriptional complex as a mediator of lymphangiogenesis and lymph$45,938
R01 · FY2013 · CA · contact PI
The Six1/Eya Transcriptional complex as a mediator of lymphangiogenesis and lymph$367,766
R01 · FY2012 · CA · contact PI
The Six1/Eya Transcriptional complex as a mediator of lymphangiogenesis and lymph$48,870
R01 · FY2012 · CA · contact PI
Identify inhibitors of the Six1/Eya interaction using high throughput screening$37,840
R03 · FY2012 · DA
TRAIL Receptor Signaling in Human Tumors$412,266
R01 · FY2011 · CA
The Six1/Eya Transcriptional complex as a mediator of lymphangiogenesis and lymph$313,076
R01 · FY2011 · CA · contact PI
Role of Six1 in EMT and Tumor Progression$253,325
R01 · FY2011 · CA · contact PI
Identify inhibitors of the Six1/Eya interaction using high throughput screening$37,190
R03 · FY2011 · DA
Identify inhibitors of the Eya phosphatase activity using high throughput screeni$36,717
R03 · FY2011 · DA
The Six1/Eya Transcriptional complex as a mediator of lymphangiogenesis and lymph$36,121
R01 · FY2011 · CA · contact PI
TRAIL Receptor Signaling in Human Tumors$426,028
R01 · FY2010 · CA
Role of Six1 in EMT and Tumor Progression$252,180
R01 · FY2010 · CA · contact PI
Identify inhibitors of the Eya phosphatase activity using high throughput screeni$37,200
R03 · FY2010 · DA
TRAIL Receptor Signaling in Human Tumors$419,924
R01 · FY2009 · CA
Role of Six1 in EMT and Tumor Progression$252,213
R01 · FY2009 · CA · contact PI
CORE--ANIMAL$110,089
P01 · FY2009 · HD · contact PI
TRAIL Receptor Signaling in Human Tumors$409,028
R01 · FY2008 · CA
Role of Six1 in EMT and Tumor Progression$253,317
R01 · FY2008 · CA · contact PI
CORE--ANIMAL$106,884
P01 · FY2008 · HD · contact PI
Role of Six1 in EMT and Tumor Progression$191,717
R01 · FY2007 · CA · contact PI
CORE--ANIMAL$88,568
P01 · FY2007 · HD · contact PI
HSIX1 in cell cycle control and tumorigenesis$61,600
R01 · FY2007 · CA · contact PI
HSIX1 in cell cycle control and tumorigenesis$267,678
R01 · FY2006 · CA · contact PI
CORE--ANIMAL$84,404
P01 · FY2006 · HD · contact PI
HSIX1 in cell cycle control and tumorigenesis$274,120
R01 · FY2005 · CA
CORE--ANIMAL$81,945
P01 · FY2005 · HD
HSIX1 in cell cycle control and tumorigenesis$273,675
R01 · FY2004 · CA
HSIX1 in cell cycle control and tumorigenesis$271,450
R01 · FY2003 · CA
HSIX1 in cell cycle control and tumorigenesis$268,780
R01 · FY2002 · CA